Evidence map›Paper›PMID 29246124›Full record

ArticleBMC cancer2017

Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.

Kanchan Kumari, Sunita Keshari, Debomita Sengupta, Surendra C Sabat, Sandip K Mishra

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Potential applications of artemisinins in ocular diseases.International journal of ophthalmology · 2019
    Review
  15. Antitumor Research on Artemisinin and Its Bioactive Derivatives.Natural products and bioprospecting · 2018
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Kanchan KumariCancer Biology Laboratory, Institute of Life Sciences (Government of India), Nalco Square, Bhubaneswar, Odisha, 751023, India.
Sunita KeshariNational Central University, Chungli, Taiwan.
Debomita SenguptaDepartment of Molecular Medicine, Bose Institute, Kolkata, India.
Surendra C SabatMolecular biology of abiotic stress, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, 751023, India.
Sandip K MishraCancer Biology Laboratory, Institute of Life Sciences (Government of India), Nalco Square, Bhubaneswar, Odisha, 751023, India. sandipkmishra@hotmail.com.
Government of India · INBose Institute · INInstitute of Life Sciences · INNational Central University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWell-known anti-malarial drug artemisinin exhibits potent anti-cancerous activities. In-vivo and in-vitro studies showed its anti-tumor and immunomodulatory properties signifying it as a potent drug candidate for study. The studies of mechanisms of cell movement are relevant which can be understood by knowing the involvement of genes in an effect of a drug. Although cytotoxicity and anti-proliferative activity of artemisinin is evident, the genes participating in its anti-migratory and reduced invasive effect are not well studied. The present study reports the alteration in the expression of 84 genes involved in cell motility upon artemisinin treatment in MCF-7 breast cancer cells using pathway focused gene expression PCR array. In addition, the effect of artemisinin on epigenetic modifier HDACs is studied.

methodsWe checked the functional stimulus of artemisinin on cell viability, migration, invasion and apoptosis in breast cancerous cell lines. Using qRT-PCR and western blot, we validated the altered expression of relevant genes associated with proliferation, migration, invasion, apoptosis and mammary gland development.

resultsArtemisinin inhibited cell proliferation of estrogen receptor negative breast cancer cells with fewer efficacies in comparison to estrogen receptor positive ones. At the same time, cell viability and proliferation of normal breast epithelial MCF10A cells was un-affected. Artemisinin strongly inhibited cancer cell migration and invasion. Along with orphan nuclear receptors (ERRα, ERRβ and ERRγ), artemisinin altered the ERα/ERβ/PR/Her expression status of MCF-7 cells. The expression of genes involved in the signaling pathways associated with proliferation, migration, invasion and apoptosis was significantly altered which cooperatively resulted into reduced growth promoting activities of breast cancer cells. Interestingly, artemisinin exhibited inhibitory effect on histone deacetylases (HDACs).

conclusionsUpregulated expression of tumor suppressor genes along with reduced expression of oncogenes significantly associated with growth stimulating signaling pathways in response to artemisinin treatment suggests its efficacy as an effective drug in breast cancer treatment.

Indexed as

Antineoplastic AgentsApoptosisArtemisininsBreast NeoplasmsCell MovementCell ProliferationCell SurvivalEpigenesis, GeneticFemaleGene Expression ProfilingGenes, Tumor SuppressorHistone Deacetylase InhibitorsHistone DeacetylasesHumansMCF-7 CellsNeoplasm InvasivenessAntineoplastic AgentsartemisininArtemisininsHistone Deacetylase InhibitorsHistone DeacetylasesBreast cancerHDACsInvasionMigrationProliferation

Identifiers

PMID29246124
PMCPMC5732364
OpenAlexW2773324279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.